Biogen Idec and UCB have signed an exclusive agreement under which UCB will commercialize Biogen products in South Korea, Hong Kong, Thailand, Singapore, Malaysia and Taiwan, and both will develop and commercialize products in China.
 
Biogen Idec will supply UCB with its portfolio of multiple sclerosis (MS) therapies and investigational candidates, including TECFIDERA, FAMPYRA, AVONEX, TYSABRI, PLEGRIDY and Daclizumab High-Yield Process (DAC HYP). The agreement also includes Biogen’s investigational long-acting recombinant candidates for hemophilia A and B, ELOCTATE and ALPROLIX.
 
“Our goal is to bring our innovative therapies to patients around the world as quickly and efficiently as possible,” said Carlos Dourado, senior vice president, Emerging Markets at Biogen Idec. “By leveraging UCB’s extensive resources, expertise and infrastructure in Asia, we believe we can grow our footprint in critical Asian markets, get our therapies to patients more quickly and create a foundation for further commercial success in this region.”
 
“As a patient-centric biopharmaceutical company, UCB is delighted to work with Biogen Idec on delivering some of the most important breakthrough products in the treatment of multiple sclerosis and hemophilia to patients in Asia,” said Mohamed Chaoui, head of Asia Pacific at UCB. “This partnership is a strong complement in our goal to offer innovative specialty care therapeutic options to patients suffering from severe diseases. It further supports our strategic goal to strengthen our leadership and expertise in biologics in both neurology and immunology in China and the Asian region.”